Diagnosis of adolescent polycystic ovary syndrome

Steroids

Volumn 78, Issue 8, 2013, Pages 751-754

  Hardy, Tristan S E ^a,b   Norman, Robert J ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Adolescence; Anovulation; Menstrual irregularity; Polycystic ovaries; Polycystic ovary syndrome

Indexed keywords

METFORMIN; ORAL CONTRACEPTIVE AGENT; SPIRONOLACTONE;

ADOLESCENT DISEASE; ARTICLE; ECHOGRAPHY; HUMAN; HYPERANDROGENISM; LIFESTYLE MODIFICATION; METABOLIC DISORDER; MORPHOLOGY; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; PRESCRIPTION;

EID: 84891903651     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2013.04.011     Document Type: Article

References (53)

1. Bekx T, Connor EC, Allen DB. Characteristics of adolescents presenting to a multidisciplinary clinic for polycystic ovarian syndrome. J Pediatr Adolesc Gynecol 2010;23:7-10.
2. Codner E, Villarroel C, Eyzaguirre FC, Lopez P, Merino PM, Perez-Bravo F, et al. Polycystic ovarian morphology in postmenarchal adolescents. Fertil Steril 2011;95:702-6.
3. Biro FM, Emans SJ. Whither PCOS? The challenges of establishing hyperandrogenism in adolescent girls. J Adol Health 2008;43:103-5.
4. Teede HJ, Misso ML, Deeks AA, Moran LJ, Stuckey BG, Wong JL, et al. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med J Aust 2011;195(6):S65-S112.
5. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007;370:685-97.
6. March WA, Moore VM, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010;25(2):544-51.
7. Hassan A, Gordon CM. Polycystic ovary syndrome update in adolescence. Curr Opin Pediatr 2007;19:389-97.
8. Bonny AE, Appelbaum H, Lancon Connor E, Cromer B, DiVasta A, Gomez-Lobo V, et al. NASPAG Research Committee. Clinical Variability in Approaches to Polycystic Ovary Syndrome. J Pediatr Adolesc Gynecol 2012;25:259-61.
9. Bhattacharya SM, Ghosh M. Insulin resistance and adolescent girls with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2010;23:158-61.
10. Fernandes AR, de Sa Rosa e Silva AC, Romao GS, Pata MC, dos Reis RM. Insulin resistance in adolescents with menstrual irregularities. J Pediatr Adolesc Gynecol 2005;18(4):269-74.
11. Trottier A, Battista M, Geller DH, Moreau B, Carpentier AC, Simoneau-Roy J, et al. Adipose tissue insulin resistance in peripubertal girls with first-degree family history of polycystic ovary syndrome. Fertil Steril 2012;98:1627-34.
12. Bhattacharya SM, Jha A. Prevalence and risk of metabolic syndrome in adolescent Indian girls with polycystic ovary syndrome using the 2009 'joint interim criteria'. J Obstet Gynaecol Res 2011;37(10):1303-7.
13. Roe AH, Prochaska E, Smith M, Sammel M, Dokras A. Using the androgen excess-PCOS society criteria to diagnose polycystic ovary syndrome and the risk of metabolic syndrome in adolescents. J Pediatr 2013;162(5):937-41. Epub ahead of print.
14. Rossi B, Sukalich S, Droz J, Griffin A, Cook S, Blumkin A, et al. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:4780-6.
15. Broder-Fingert S, Shah B, Kessler M, Pawelczak M, David R. Evaluation of adolescents for polycystic ovary syndrome in an urban population. J Clin Res Ped Endocrinol 2009;1(4):188-93.
16. Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol 2010;203:201.e1-5.
17. The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod 2012;27(1):14-24.
18. van Hooff MHA, Voorhorst FJ, Kaptein MBH, Hirasing RA, Koppenaal C, Schoemaker J. Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years. Hum Reprod 2004;19(2):383-92.
19. Bronstein J, Tawdekar S, Liu Y, Pawelczak M, David R, Shah B. Age of onset of polycystic ovarian syndrome in girls may be earlier than previously thought. J Pediatr Adolesc Gynecol 2011;24:15-20.
20. Carroll J, Saxena R, Welt CK. Environmental and genetic factors influence age at menarche in women with polycystic ovary syndrome. J Pediatr Endocrinol Metab 2012;25(5-6):459-66.
21. Khan U. Polycystic ovary syndrome in adolescents. J Pediatr Adolesc Gynecol 2007;20:101-4.
22. Mortensen M, Rosenfield RL, Littlejohn E. Functional significance of polycysticsize ovaries in healthy adolescents. J Clin Endocrinol Metab 2006;91:3786-90.
23. Alsamarai S, Adams JM, Murphy MK, Post MD, Hayden DL, Hall JE, et al. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J Clin Endocrinol Metab 2009;94:4961-70.
24. Hickey M, Doherty DA, Atkinson H, Sloboda DM, Franks S, Norman RJ, et al. Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis. Hum Reprod 2011;26(6):1469-77.
25. Kristensen SL, Ramlau-Hansen CH, Ernst E, Olsen SF, Bonde JP, Vested A, et al. A very large proportion of young Danish women have polycystic ovaries: is a revision of the Rotterdam criteria needed? Hum Reprod 2010;25(12): 3117-22.
26. Venturoli S, Porcu E, Fabbri R, Pluchinotta V, Ruggeri S, Macrelli S, et al. Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence. Pediatr Res 1995;38:974-80.
27. Chen Y, Yang D, Li L, Chen X. The role of ovarian volume as a diagnostic criterion for chinese adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2008;21:347-50.
28. Lujan ME, Jarrett BY, Brooks ED, Reines JK, Peppin AK, Muhn N, et al. Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume. Hum Reprod 2013;28(5): 1361-8. Epub ahead of print.
29. Yoo RY, Sirlin CB, Gottschalk M, Chang RJ. Ovarian imaging by magnetic resonance in obese adolescent girls with polycystic ovary syndrome: a pilot study. Fertil Steril 2005;84(4):985-95.
30. Lam PM, Raine-Fenning N. The role of three-dimensional ultrasonography in polycystic ovary syndrome. Hum Reprod 2006;21(9):2209-15.
31. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Task force on the phenotype of the polycystic ovary syndrome of the androgen excess and PCOS society. The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456-88.
32. National Institutes of Health. Evidence-based Methodology Workshop on Polycystic Ovary Syndrome: prevention.nih.gov/workshops/2012/pcos/, (accessed 6th April 2013).
33. Huppert J, Chiodi M, Hillard PJA. Clinical and metabolic findings in adolescent females with hyperandrogenism. J Pediatr Adolesc Gynecol 2004;17:103-8.
34. Fruzzetti F, Perini D, Lazzarini V, Parrini D, Genazzani AR. Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels. Fertil Steril 2009;92:626-34.
35. Hart R, Doherty DA, Mori T, Huang R, Norman RJ, Franks S, et al. Extent of metabolic risk in adolescent girls with features of polycystic ovary syndrome. Fertil Steril 2011;95:2347-53.
36. Pinola P, Lashen H, Bloigu A, Puukka K, Ulmanen M, Ruokonen A, et al. Menstrual disorders in adolescence: a marker for hyperandrogenaemia and increased metabolic risks in later life? Finnish general population-based birth cohort study. Hum Reprod 2012;27(11):3279-86.
37. Rosenfield RL. Clinical review: identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92(3):787-96.
38. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007;92(2):405-13.
39. Roe AH, Dokras A. The diagnosis of polycystic ovary syndrome in adolescents. Rev Obstet Gynecol 2011;4(2):45-51.
40. Villarroel C, Merino PM, Lopez P, Eyzaguire FC, Van Velzen A, Iniguez G, et al. Polycystic ovarian morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone. Hum Reprod Sci 2011;26(10): 2861-68.
41. Sir-Petermann T, Ladron de Guevara A, Codner E, Preisler J, Crisosto N, Echiburu B, et al. Relationship between anti-Mullerian hormone (AMH) and insulin levels during different tanner stages in daughters of women with polycystic ovary syndrome. Reprod Sci 2012;19(4):383-90.
42. Siow Y, Kives S, Hertweck P, Perlman S, Fallat ME. Serum mullerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome. Fertil Steril 2005;84:938-44.
43. Crisosto N, Codner E, Maliqueo M, Echiburu B, Sanchez F, Cassorla F, et al. Anti- Mullerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:2739-43.
44. Hart R, Doherty DA, Norman RJ, Franks S, Dickinson JE, Hickey M, et al. Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome. Fertil Steril 2010;94: 1118-21.
45. Hardy T, De Sousa S, Norman RJ. Polycystic ovary syndrome: prognosis and risk of comorbidity. In: Diamanti-Kandarakis E, Nader S, Panidis D, editors. Novel Insights into the Pathophysiology and Treatment of PCOS. London: Future Medicine Ltd; 2013. p. 122-34.
46. Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the androgen excess and polycystic ovary syndrome society. Hum Reprod Update 2012;18(2):146-70.
47. Bhattacharya SM, Jha A. Comparative study of the effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drosperinone in patients with polycystic ovary syndrome. Fertil Steril 2012;98(4):1053-9.
48. Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-termtherapy of hirsute patients. Clin Endocrinol (Oxf) 2000;52(5): 587-94.
49. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011;7:CD007506.
50. Lass N, Kleber M, Winkel K, Wunsch R, Reinehr T. Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls. J Clin Endocrinol Metab 2011;96:3533-40.
51. Freemark M. Management of adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2011;96(11):3354-6.
52. Ibanez L, Lopez-Bermejo A, Diaz M, Marcos MV, de Zegher F. Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhoea in adolescence. J Clin Endocrinol Metab 2011;96(8):E1262.
53. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002;87(5):2013-7.